Daré Bioscience, Inc. filings document a women’s health biotechnology issuer with product and pipeline disclosures, operating-result updates, and capital-structure activity. Recent 8-K reports cover financial results, Regulation FD presentations, and unregistered sales tied to a Regulation A unit offering composed of Series A Convertible Preferred Stock and warrants to purchase common stock.
Proxy and governance filings describe annual meeting matters, director elections, executive compensation, equity awards, board classification, and stockholder voting procedures. The record also includes disclosure around offering statements, preferred-stock conversion terms, warrant exercise terms, and financing activity associated with advancing women’s health products and clinical programs.
Daré Bioscience, Inc. (DARE) is asking stockholders to approve the potential future issuance of up to 8,934,345 common shares upon exercise of warrants issued in its August 2026 financing. The special meeting is scheduled for November 10, 2026; a second proposal would authorize an adjournment, if needed, to solicit votes for the warrant proposal. The board recommends voting “FOR” both proposals.
If approved, the warrants become exercisable, but holders are not required to exercise them. Assuming full exercise and cash payment, Daré would issue 8,934,345 shares—approximately 45.4% of its common shares outstanding on September 30, 2026—and receive approximately $12.4 million in gross proceeds. Exercise is subject to a 4.99% beneficial ownership limit, or 9.99% for holders electing that limit. The common warrants have a $1.37 exercise price; placement agent warrants have a $2.1235 exercise price. Daré had 19,669,083 common shares outstanding as of September 30, 2026.
Daré Bioscience, Inc. (DARE) received Nasdaq notice that its common stock’s closing bid had been below the $1.00 per share minimum for 30 consecutive business days. The notice has no immediate effect on its Nasdaq Capital Market listing. Daré has until March 29, 2027, the end of an initial 180-calendar-day period, to regain compliance. A closing bid of at least $1.00 for 10 consecutive business days would meet the price test, unless Nasdaq Staff extends that period.
If Daré does not regain compliance, it may qualify for another 180-calendar-day period by meeting the other specified listing standards and providing written notice of its intention to cure the deficiency, by effecting a reverse stock split if necessary. If Daré is ineligible for that period or Staff believes it cannot cure the deficiency, Staff would provide written notice that the stock is subject to delisting; Daré may then appeal to a Nasdaq Hearing Panel. Daré said it will monitor the closing bid and consider options, and stated there can be no assurance it will regain compliance or meet other continued-listing requirements.
Daré Bioscience, Inc. furnished a corporate presentation dated October 1, 2026, for use in meetings with securities market participants and others beginning that day. The company plans to post it in the Investors section of its website under “Presentations, Events & Webcasts,” in the “Presentations” subsection.
Daré Bioscience, Inc. (DARE) is asking stockholders to approve the potential issuance of up to 8,934,345 common shares upon exercise of warrants from its August 2026 financing, as required under Nasdaq listing rules. The warrants cannot be exercised until stockholders approve Proposal 1, and holders are not required to exercise them. Common warrants have a $1.37-per-share exercise price; placement-agent warrants have a $2.1235-per-share exercise price.
If all warrants were exercised in full for cash, DARE would issue 8,934,345 shares—approximately 45% of its 19,669,083 shares outstanding as of September 18, 2026—and receive approximately $12.4 million in gross proceeds. A holder’s exercise is generally limited to ownership of 4.99% of outstanding shares, with an increase up to 9.99% permitted under the warrant terms after at least 61 days’ prior notice. Proposal 2 asks stockholders to authorize an adjournment to seek additional votes if needed. The board recommends voting “FOR” both proposals.
Daré Bioscience, Inc. (DARE) reports that on September 10, 2026, its board of directors approved an amendment to the company’s Third Amended and Restated By-Laws to change the stockholder meeting quorum standard. The quorum requirement was reduced from holders of a majority in voting power of outstanding shares entitled to vote to holders of at least one-third of the voting power of such shares, effective immediately. The amendment text is provided as an exhibit and incorporated by reference.
Daré Bioscience, Inc. (DARE) furnished a corporate presentation as an exhibit to a current report under a Regulation FD disclosure. The presentation is dated September 9, 2026 and may be used in meetings with securities market participants and others starting on that date.
The presentation will also be made available in the Investors section of Daré’s website under “Presentations, Events & Webcasts.” The furnished materials, including Exhibit 99.1, are not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other securities filings, except if specifically referenced.
Daré Bioscience, Inc. (DARE) has filed a resale prospectus covering up to 8,934,345 shares of common stock for selling stockholders. This includes 8,759,162 shares issuable upon exercise of Series A and Series B common warrants and 175,183 shares issuable upon exercise of placement agent warrants. Daré is not selling shares and will not receive proceeds from stockholder resales, but may receive up to approximately $12.4 million if all warrants are exercised for cash at exercise prices of $1.37 and $2.1235 per share.
The warrants were issued in an August 2026 financing that combined a registered direct offering with a concurrent private placement and are exercisable only after required Nasdaq stockholder approval, with built-in beneficial ownership limits of 4.99% or 9.99%. Shares outstanding were 19,669,083 as of August 20, 2026; this is a baseline figure, not the amount being offered. Daré highlights a women’s health–focused pipeline, a new Section 503B compounding and consumer health strategy, substantial ongoing capital needs, a prior going-concern emphasis in its 2025 audit report, and continued risk around maintaining its Nasdaq Capital Market listing pending a panel decision.
Dare Bioscience, Inc. (DARE) reports that Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton have jointly filed as significant shareholders on a Schedule 13G. Each reporting person is deemed to beneficially own 1,094,890 shares of common stock, representing 5.65% of the outstanding common stock, with sole voting and dispositive power over these shares.
The ownership position is structured as (i) 1,094,890 common shares, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants. A 4.99% beneficial ownership limitation in the warrants caps how many shares can be owned through conversion at any time, so aggregate beneficial ownership is limited to 1,094,890 shares.
Daré Bioscience, Inc. (DARE) has filed a Form S-1 to register for resale up to 8,934,345 shares of common stock issued or issuable to investors and the placement agent from an August 2026 financing. All shares are being offered by selling stockholders; Daré is not selling shares in this registration.
The registered shares consist of 8,759,162 shares underlying Series A and Series B common warrants (including pre-funded warrants) and 175,183 shares underlying placement agent warrants. Daré will not receive proceeds from stockholder resales, but could receive up to about $12.4 million if all warrants are exercised for cash, which it plans to use for working capital, 503B compounding and consumer health initiatives, and R&D.
Daré describes a women’s health portfolio spanning contraception, menopause, sexual and vaginal health, and infectious disease, plus a dual-path model using both FDA approval and Section 503B compounding. It highlights new 503B and consumer products, significant ongoing capital needs, a recent Nasdaq Listing Rule 5550(b) deficiency under review by a Nasdaq hearing panel, and an auditor’s going-concern paragraph in its 2025 financial statements.